| Literature DB >> 30999951 |
Yingzhong Yang1,2,3, Hui Du4, Yuhong Li5, Wei Guan5, Feng Tang4,6,7, Qin Ga4,6,7, Ri-Li Ge4,6,7.
Abstract
BACKGROUND: High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic edema which occurs in unacclimatized individuals after rapid ascent to high altitude. NR3C1 gene encodes for glucocorticoid receptor (GR) which plays an important role in stress and inflammation. This study aimed to investigate the association of NR3C1 polymorphisms with the susceptibility to HAPE in Han Chinese.Entities:
Keywords: HAPE; NR3C1; Polymorphism; Susceptibility
Mesh:
Substances:
Year: 2019 PMID: 30999951 PMCID: PMC6472084 DOI: 10.1186/s40101-019-0194-1
Source DB: PubMed Journal: J Physiol Anthropol ISSN: 1880-6791 Impact factor: 2.867
High-altitude exposures and physiological phenotypes for the study populations
| Groups | Subjects ( | Gender | Altitude (m) | Average age (year) | HGB (g/dL) | Hct (%) | HR (b/m) | SPO2 (%) |
|---|---|---|---|---|---|---|---|---|
| HAPE-p | 133 | Male | 3760 | 40.20 ± 9.91 | 157.24 ± 15.24* | 47.79 ± 4.97* | 109.73 ± 14.85* | 62.46 ± 11.89* |
| HAPE-r | 135 | Male | 3760 | 40.92 ± 5.15 | 172.80 ± 14.54 | 50.74 ± 8.15 | 80.84 ± 12.03 | 88.85 ± 4.17 |
Values are means ± SD. P < 0.05 vs HAPE-r
HAPE-p high-altitude pulmonary edema patients, HAPE-r high-altitude pulmonary edema resistant (control), HGB hemoglobin, Hct hematocrit, HR heart rate, SPO oxyhemoglobin saturation
SNPs information of the NR3C1 gene and the Hardy–Weinberg Equilibrium (HWE) in the current population
| SNP ID | Gene | Band | Position | Alleles A/B | Global MAF | ||
|---|---|---|---|---|---|---|---|
| HAPE-p | HAPE-r | ||||||
| rs174048 |
| 5q31-q32 | 143270839 | C/T | C = 0.1014/508 | 0.491 | 0.216 |
| rs17287745 |
| 5q31-q32 | 143275450 | G/A | G = 0.2528/1266 | 0.678 | 0.427 |
| rs17209237 |
| 5q31-q32 | 143277647 | G/A | G = 0.1542/772 | 0.543 | 0.394 |
| rs6198 |
| 5q31-q32 | 143278056 | C/T | C = 0.0839/420 | 0.965 | 0.826 |
| rs6191 |
| 5q31-q32 | 143278591 | A/C | A = 0.4016/2011 | 0.473 | 0.855 |
| rs10482704 |
| 5q31-q32 | 143282198 | A/C | A = 0.0080/40 | 1 | 0.966 |
| rs258751 |
| 5q31-q32 | 143282715 | A/G | A = 0.0547/274 | 0.491 | 0.216 |
| rs17209251 |
| 5q31-q32 | 143289658 | G/A | G = 0.1472/737 | 0.585 | 0.380 |
| rs258813 |
| 5q31-q32 | 143295125 | A/G | A = 0.2312/1158 | 0.323 | 0.082 |
| rs6188 |
| 5q31-q32 | 143300779 | A/C | A = 0.2306/1155 | 0.323 | 0.072 |
| rs33388 |
| 5q31-q32 | 143317730 | A/T | A = 0.3934/1970 | 0.473 | 0.759 |
| rs33389 |
| 5q31-q32 | 143320934 | T/C | T = 0.1064/533 | 0.491 | 0.236 |
| rs2918417 |
| 5q31-q32 | 143346605 | T/C | T = 0.2236/1120 | 0.321 | 0.072 |
| rs6877893 |
| 5q31-q32 | 143347628 | G/A | G = 0.4030/2018 | 0.320 | 0.952 |
| rs10482642 |
| 5q31-q32 | 143348466 | C/T | C = 0.0988/495 | 0.965 | 0.826 |
| rs17399352 |
| 5q31-q32 | 143375125 | C/T | C = 0.1394/698 | 0.798 | 0.272 |
| rs2963155 |
| 5q31-q32 | 143376439 | G/A | G = 0.2228/1116 | 0.553 | 0.075 |
| rs2963156 |
| 5q31-q32 | 143378931 | T/C | T = 0.1615/809 | 0.717 | 0.256 |
| rs1866388 |
| 5q31-q32 | 143380220 | G/A | G = 0.2139/1071 | 0.459 | 0.160 |
| rs41423247 |
| 5q31-q32 | 143399010 | C/G | C = 0.2546/1275 | 0.821 | 0.592 |
| rs6189 |
| 5q31-q32 | 143400774 | T/C | T = 0.0106/53 | 0.965 | 0.966 |
| rs4634384 |
| 5q31-q32 | 143401132 | C/T | C = 0.3972/1989 | 0.671 | 0.513 |
| rs10052957 |
| 5q31-q32 | 143407136 | A/G | A = 0.2212/1108 | 0.323 | 0.074 |
| rs9324924 |
| 5q31-q32 | 143412919 | T/G | T = 0.4808/2408 | 0.574 | 0.042 |
| rs7701443 |
| 5q31-q32 | 143413085 | A/G | G = 0.4605/2306 | 0.906 | 0.420 |
| rs4244032 |
| 5q31-q32 | 143415160 | G/A | G = 0.1326/664 | 0.000 | 0.002 |
| rs4607376 |
| 5q31-q32 | 143416967 | A/G | G = 0.3966/1986 | 0.782 | 0.724 |
| rs12656106 |
| 5q31-q32 | 143429382 | C/G | C = 0.3413/1709 | 0.840 | 0.429 |
| rs12655166 |
| 5q31-q32 | 143429707 | C/T | 0.287 | 0.780 | |
| rs12521436 |
| 5q31-q32 | 143438042 | A/G | A = 0.2776/1390 | 0.581 | 0.291 |
Alleles A/B = minor/major alleles, Global MAF = global minor allele frequency
HAPE-p high-altitude pulmonary edema patients, HAPE-r high-altitude pulmonary edema resistant (control)
Comparison of genotype distributions and allele frequencies for SNPs associated with HAPE risk under the dominant and recessive model in both groups, respectively
| SNP | Genotype/allele | HAPE-p ( | HAPE-r ( | OR (95% CI) |
|
|
|---|---|---|---|---|---|---|
| rs17287745 | ||||||
| Genotype | AA | 98 (73.7) | 81 (60.0) | |||
| AG | 33 (24.8) | 45 (33.3) | 1.650 (0.964–2.823) | 3.365 | 0.067 | |
| GG | 2 (1.5) | 9 (6.7) | 5.444 (1.144–25.915) | 5.558 |
| |
| Allele | A | 229 (86.1) | 207 (76.7) | |||
| G | 37 (13.9) | 63 (23.3) | 1.884 (1.204–2.946) | 7.841 |
| |
| Dominant model | AA | 98 (73.7) | 81 (60.0) | |||
| AG + GG | 35 (26.3) | 54 (40.0) | 1.867 (1.113–3.131) | 5.656 |
| |
| rs17209237 | ||||||
| Genotype | AA | 95 (72) | 83 (62.4) | |||
| AG | 35 (26.5) | 42 (31.6) | 1.373 (0.803–2.349) | 1.348 | 0.246 | |
| GG | 2 (1.5) | 8 (6.0) | 4.578 (0.946–22.166) | 4.222 |
| |
| Allele | A | 225 (85.2) | 208 (78.2) | |||
| G | 39 (14.8) | 58 (21.8) | 1.609 (1.028–2.517) | 4.382 |
| |
| Dominant model | AA | 95 (72.0) | 83 (62.4) | |||
| AG + GG | 37 (28.0) | 50 (37.6) | 1.547 (0.922–2.594) | 2.748 | 0.097 | |
| rs6191 | ||||||
| Genotype | CC | 88 (66.7) | 69 (51.9) | |||
| CA | 38 (28.8) | 53 (39.8) | 1.779 (1.055–2.999) | 4.709 |
| |
| AA | 6 (4.5) | 11 (8.3) | 2.338 (0.824–6.638) | 2.661 | 0.103 | |
| Allele | C | 214 (81.1) | 191 (71.8) | |||
| A | 50 (18.9) | 75 (28.2) | 1.681 (1.118–2.526) | 6.299 |
| |
| Dominant model | CC | 88 (66.7) | 69 (51.9) | |||
| CA + AA | 44 (33.3) | 64 (48.1) | 1.855 (1.129–3.048) | 5.999 |
| |
| rs17209251 | ||||||
| Genotype | AA | 94 (72.3) | 84 (62.7) | |||
| GA | 34 (26.2) | 42 (31.3) | 1.382 (0.806–2.371) | 1.388 | 0.239 | |
| GG | 2 (1.5) | 8 (6.0) | 4.476 (0.925–21.671) | 4.079 |
| |
| Allele | A | 222 (85.4) | 210 (78.4) | |||
| G | 38 (14.6) | 58 (21.6) | 1.614 (1.028–2.532) | 4.380 |
| |
| Dominant model | AA | 94 (72.3) | 84 (62.7) | |||
| GA + GG | 36 (27.7) | 50 (37.3) | 1.554 (0.924–2.614) | 2.781 | 0.095 | |
| rs6188 | ||||||
| Genotype | CC | 112 (84.2) | 98 (73.1) | |||
| CA | 21 (15.8) | 36 (26.9) | 1.959 (1.072–3.579) | 4.877 |
| |
| AA | 0 (0.0) | 0 (0.0) | ||||
| Allele | C | 245 (92.1) | 232 (86.6) | |||
| A | 21 (7.9) | 36 (13.4) | 1.810 (1.027–3.193) | 4.294 |
| |
| Dominant model | CC | 112 (84.2) | 98 (73.1) | |||
| CA + AA | 21 (15.8) | 36 (26.9) | 1.959 (1.072–3.579) | 4.877 |
| |
| rs33388 | ||||||
| Genotype | TT | 88 (66.7) | 69 (51.1) | |||
| AT | 38 (28.8) | 54 (40) | 1.812 (1.076–3.052) | 5.047 |
| |
| AA | 6 (4.5) | 12 (8.9) | 2.551 (0.911–7.141) | 3.352 | 0.067 | |
| Allele | T | 214 (81.1) | 192 (71.1) | |||
| A | 50 (18.9) | 78 (28.9) | 1.739 (1.160–2.607) | 7.251 |
| |
| Dominant model | TT | 88 (66.7) | 69 (51.1) | |||
| AT+AA | 44 (33.3) | 66 (48.9) | 1.913 (1.166–3.138) | 6.666 |
| |
| rs2918417 | ||||||
| Genotype | CC | 111 (84.1) | 98 (73.1) | |||
| CT | 21 (15.9) | 36 (26.9) | 1.942 (1.063–3.548) | 4.741 |
| |
| TT | 0 (0.0) | 0 (0.0) | ||||
| Allele | C | 243 (92.0) | 232 (86.6) | |||
| T | 21 (8.0) | 36 (13.4) | 1.796 (1.018–3.167) | 4.172 |
| |
| Dominant model | CC | 111 (84.1) | 98 (73.1) | |||
| CT + TT | 21 (15.9) | 36 (26.9) | 1.942 (1.063–3.548) | 4.741 |
| |
| rs6877893 | ||||||
| Genotype | AA | 87 (68) | 68 (51.1) | |||
| AG | 35 (27.3) | 54 (40.6) | 1.974 (1.161–3.356) | 6.385 |
| |
| GG | 6 (4.7) | 11 (8.3) | 2.346 (0.826–6.663) | 2.678 | 0.102 | |
| Allele | A | 209 (81.6) | 190 (71.4) | |||
| G | 47 (18.4) | 76 (28.6) | 1.779 (1.176–2.689) | 7.553 |
| |
| Dominant model | AA | 87 (68.0) | 68 (51.1) | |||
| AG + GG | 41 (32.0) | 65 (48.9) | 2.028 (1.226–3.356) | 7.670 |
| |
| rs1866388 | ||||||
| Genotype | AA | 116 (87.9) | 105 (78.4) | |||
| GA | 16 (12.1) | 29 (21.6) | 2.002 (1.030–3.894) | 4.288 |
| |
| GG | 0 (0.0) | 0 (0.0) | ||||
| Allele | A | 248 (93.9) | 239 (89.2) | |||
| G | 16 (6.1) | 29 (10.8) | 1.881 (0.996–3.552) | 3.892 |
| |
| Dominant model | AA | 116 (87.9) | 105 (78.4) | |||
| AG + GG | 16 (12.1) | 29 (21.6) | 2.002 (1.030–3.894) | 4.288 |
| |
| rs41423247 | ||||||
| Genotype | GG | 93 (69.9) | 76 (56.3) | |||
| CG | 36 (27.1) | 49 (36.3) | 1.666 (0.984–2.819) | 3.636 | 0.057 | |
| CC | 4 (3.0) | 10 (7.4) | 3.059 (0.923–10.142) | 3.633 | 0.057 | |
| Allele | G | 222 (83.5) | 201 (74.4) | |||
| C | 44 (16.5) | 69 (25.6) | 1.732(1.134–2.645) | 6.544 |
| |
| Dominant model | GG | 93 (69.9) | 76 (56.3) | |||
| CG + CC | 40 (30.1) | 59 (43.7) | 1.805 (1.091–2.985) | 5.342 |
| |
| rs4634384 | ||||||
| Genotype | TT | 87 (67.4) | 68 (51.1) | |||
| CT | 37 (28.7) | 52 (39.1) | 1.798 (1.061–3.047) | 4.793 |
| |
| CC | 5 (3.9) | 13 (9.8) | 3.326 (1.131–9.786) | 5.206 |
| |
| Allele | T | 211 (81.8) | 188 (70.7) | |||
| C | 47 (18.2) | 78 (29.3) | 1.863 (1.234–2.812) | 8.894 |
| |
| Dominant model | TT | 87 (67.4) | 68 (51.1) | |||
| CT + CC | 42 (32.6) | 65 (48.9) | 1.980 (1.200–3.269) | 7.214 |
| |
| rs10052957 | ||||||
| Genotype | GG | 112 (84.2) | 99 (73.3) | |||
| GA | 21 (15.8) | 36 (26.7) | 1.939 (1.062–3.542) | 4.734 |
| |
| AA | 0 (0.0) | 0 (0.0) | ||||
| Allele | G | 245 (92.1) | 234 (86.7) | |||
| A | 21 (7.9) | 36 (13.3) | 1.795 (1.018–3.165) | 4.170 |
| |
| Dominant model | GG | 112 (84.2) | 99 (73.3) | |||
| GA + AA | 21 (15.8) | 36 (26.7) | 1.939 (1.062–3.542) | 4.734 |
| |
Data are shown as odds ratio (OR), 95% confidence interval (CI), and P values comparing HAPE patients and control group
P value in italics indicates statistical significance after comparisons
HAPE-p high-altitude pulmonary edema patients, HAPE-r high-altitude pulmonary edema resistant (control)
Fig. 1Linkage disequilibrium among the 12 SNPs of the NR3C1 gene in the HAPE-p group (a) and HAPE-r group (b). The degree of genetic linkage between these SNPs is estimated as D values. Red panels indicate that there exists a strong pairwise linkage disequilibrium between adjacent SNPs whereas white panels indicate that the linkage disequilibrium is weak or non-existent
Haplotype analysis for 12 SNPs of the NR3C1 gene in HAPE and control groups
| Haplotype | HAPE-p (freq) | HAPE-r (freq) |
| Odds ratio [95%CI] | |
|---|---|---|---|---|---|
| AAAAAATGGCCA | 11.47 (0.043) | 21.87 (0.081) | 3.502 | 0.0613 | 0.500 [0.239~1.046] |
| AACACTCAAGTG | 206.53 (0.776) | 174.13 (0.645) | 11.206 |
| 2.044 [1.339~3.120] |
| GGAGCACGACCG | 24.00 (0.090) | 39.00 (0.144) | 4.127 |
| 0.573 [0.333~0.985] |
| GGCGCTCAAGTG | 8.47 (0.032) | 14.87 (0.055) | 1.857 | 0.1729 | 0.553 [0.233~1.311] |
P value in italics indicates statistical significance after comparisons, data are shown as odds ratio (OR), 95% confidence interval (CI)
HAPE-p high-altitude pulmonary edema patients, HAPE-r high-altitude pulmonary edema resistant (control), χ chi square